MedTrace Logo

Exploration of the Optimal Dosage of Cetirizine in the Treatment of Allergic Diseases in Chinese Children

NCT06288334 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-03-01

No results posted yet for this study

Summary

To obtain the pharmacokinetics of cetirizine in Chinese children with allergic disease.

Conditions

  • Allergic Disease
  • Children

Interventions

OTHER

1-3 Cetirizine Pharmacokinetic samples

Limited sampling strategy was used in this study. For each child, only 1\~3 blood samples were collected before and after cetirizine administration.

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Wei Zhou · Peking University Third Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-06
Primary Completion
2024-03-31
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06288334 on ClinicalTrials.gov